Modeling and predicting clinical efficacy for drugs targeting the tumor milieu

Nature Biotechnology

Volumn 30, Issue 7, 2012, Pages 648-657

  Singh, Mallika ^a   Ferrara, Napoleone ^b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL STUDIES; CANCER THERAPEUTICS; CLINICAL EFFICACY; CLINICAL TRIAL; HUMAN CANCER; MOUSE MODELS; PRECLINICAL STUDIES; TRANSLATABILITY; TUMOR CELLS; TUMOR MICROENVIRONMENT; TUMOR MODELS;

DESIGN OF EXPERIMENTS; DISEASES; MAMMALS;

TUMORS;

AFLIBERCEPT; AGM386; ANTI EGFL7; ANTINEOPLASTIC AGENT; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CEDIRANIB; CILENGITIDE; COLONY STIMULATING FACTOR 1; FLT3 LIGAND; ICRUCUMAB; MATRIX METALLOPROTEINASE; MOTESANIB; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN RET; RAMUCIRUMAB; REGORAFENIB; SCATTER FACTOR RECEPTOR; SORAFENIB; SUNITINIB; TB 403; TIVOZANIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANDETANIB; VASCULOTROPIN A; VASCULOTROPIN B; VASCULOTROPIN RECEPTOR; VOLOCIXIMAB; ZALTRAP;

ALLOGRAFT; ANTIANGIOGENIC THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MODEL; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHIMERA; CLINICAL TRIAL (TOPIC); DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG MECHANISM; DRUG SCREENING; FIBROBLAST; HUMAN; MOLECULARLY TARGETED THERAPY; NONHUMAN; OVERALL SURVIVAL; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN BINDING; PROTEIN EXPRESSION; REVIEW; SIGNAL TRANSDUCTION; STROMA CELL; TRANSGENIC ANIMAL; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; TUMOR VOLUME; TUMOR XENOGRAFT;

ANGIOGENESIS INHIBITORS; ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

ANIMALIA;

EID: 84863691378     PISSN: 10870156     EISSN: 15461696     Source Type: Journal    
DOI: 10.1038/nbt.2286     Document Type: Review

References (129)

1. Reichert, J.M. & Wenger, J.B. Development trends for new cancer therapeutics and vaccines. Drug Discov. Today 13, 30-37 (2008).
2. McAllister, S.S. & Weinberg, R.A. Tumor-host interactions: a far-reaching relationship. J. Clin. Oncol. 28, 4022-4028 (2010).
3. Pietras, K. & Ostman, A. Hallmarks of cancer: interactions with the tumor stroma. Exp. Cell Res. 316, 1324-1331 (2010).
4. Ferrara, N. & Kerbel, R.S. Angiogenesis as a therapeutic target. Nature 438, 967-974 (2005).
5. Weber, J. Immune checkpoint proteins: a new therapeutic paradigm for cancer-preclinical background: CTLA-4 and PD-1 blockade. Semin. Oncol. 37, 430-439 (2010).
6. Xing, F., Saidou, J. & Watabe, K. Cancer associated fibroblasts (CAFs) in tumor microenvironment. Front. Biosci. 15, 166-179 (2010).
7. Becher, O.J. & Holland, E.C. Genetically engineered models have advantages over xenografts for preclinical studies. Cancer Res. 66, 3355-3359 (2006).
8. Kerbel, R.S. Human tumor xenografts as predictive preclinical models for anticancer drug activity in humans: better than commonly perceived-but they can be improved. Cancer Biol. Ther. 2, S134-S139 (2003).
9. Sausville, E.A. & Burger, A.M. Contributions of human tumor xenografts to anticancer drug development. Cancer Res. 66, 3351-3354, discussion 3354 (2006).
10. Sharpless, N.E. & Depinho, R.A. The mighty mouse: genetically engineered mouse models in cancer drug development. Nat. Rev. Drug Discov. 5, 741-754 (2006).
11. Singh, M. & Johnson, L. Using genetically engineered mouse models of cancer to aid drug development: an industry perspective. Clin. Cancer Res. 12, 5312-5328 (2006).
12. Boehm, J.S. & Hahn, W.C. Towards systematic functional characterization of cancer genomes. Nat. Rev. Genet. 12, 487-498 (2011).
13. Tuveson, D.A. & Jacks, T. Technologically advanced cancer modeling in mice. Curr. Opin. Genet. Dev. 12, 105-110 (2002).
14. Voskoglou-Nomikos, T., Pater, J.L. & Seymour, L. Clinical predictive value of the in vitro cell line, human xenograft, and mouse allograft preclinical cancer models. Clin. Cancer Res. 9, 4227-4239 (2003).
15. Wong, K.M., Hudson, T.J. & McPherson, J.D. Unraveling the genetics of cancer: genome sequencing and beyond. Annu. Rev. Genomics Hum. Genet. 12, 407-430 (2011).
16. Heyer, J., Kwong, L.N., Lowe, S.W. & Chin, L. Non-germline genetically engineered mouse models for translational cancer research. Nat. Rev. Cancer 10, 470-480 (2010).
17. Bergers, G., Javaherian, K., Lo, K.M., Folkman, J. & Hanahan, D. Effects of angiogenesis inhibitors on multistage carcinogenesis in mice. Science 284, 808-812 (1999).
18. Francia, G., Cruz-Munoz, W., Man, S., Xu, P. & Kerbel, R.S. Mouse models of advanced spontaneous metastasis for experimental therapeutics. Nat. Rev. Cancer 11, 135-141 (2011).
19. Singh, M. et al. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumor models. J. Pathol. advance online publication, doi:10.1002/path.4053 (18 May 2012).
20. Goss, P.E. & Chambers, A.F. Does tumour dormancy offer a therapeutic target? Nat. Rev. Cancer 10, 871-877 (2010).
21. Peterson, J.K. & Houghton, P.J. Integrating pharmacology and in vivo cancer models in preclinical and clinical drug development. Eur. J. Cancer 40, 837-844 (2004).
22. Haber, D.A. et al. Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors. Cold Spring Harb. Symp. Quant. Biol. 70, 419-426 (2005).
23. Wong, H. et al. Pharmacokinetic-pharmacodynamic analysis of vismodegib in preclinical models of mutational and ligand-dependent hedgehog pathway activation. Clin. Cancer Res. 17, 4682-4692 (2011).
24. Gibbs, J.P. Prediction of exposure-response relationships to support first-in-human study design. AAPS J. 12, 750-758 (2010).
25. Maziasz, T., Kadambi, V.J., Silverman, L., Fedyk, E. & Alden, C.L. Predictive toxicology approaches for small molecule oncology drugs. Toxicol. Pathol. 38, 148-164 (2010).
26. Liang, W.C. et al. Cross-species vascular endothelial growth factor (VEGF)-blocking antibodies completely inhibit the growth of human tumor xenografts and measure the contribution of stromal VEGF. J. Biol. Chem. 281, 951-961 (2006).
27. Gerber, H.P. et al. Mice expressing a humanized form of VEGF-A may provide insights into the safety and efficacy of anti-VEGF antibodies. Proc. Natl. Acad. Sci. USA 104, 3478-3483 (2007).
28. Ekins, S. & Williams, A.J. Precompetitive preclinical ADME/Tox data: set it free on the web to facilitate computational model building and assist drug development. Lab Chip 10, 13-22 (2010).
29. Olive, K.P. et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer. Science 324, 1457-1461 (2009).
30. Van Dyke, T. Finding the tumor copycat: approximating a human cancer. Nat. Med. 16, 976-977 (2010).
31. Alley, M.C., Hollingshead, M.G., Dykes, D.J. & Waud, W.R. in Anticancer. Drug Development Guide: Preclinical Screening, Clinical Trials, and Approval, 2nd edn. (eds. Teicher, B.A. & Andrews, P.A.) 125-152 (Humana, 2004).
32. Workman, P. et al. Guidelines for the welfare and use of animals in cancer research. Br. J. Cancer 102, 1555-1577 (2010).
33. de Vries, N.A. et al. Rapid and robust transgenic high-grade glioma mouse models for therapy intervention studies. Clin. Cancer Res. 16, 3431-3441 (2010).
34. Singh, M. et al. Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models. Nat. Biotechnol. 28, 585-593 (2010).
35. LoRusso, P.M., Anderson, A.B., Boerner, S.A. & Averbuch, S.D. Making the investigational oncology pipeline more efficient and effective: are we headed in the right direction? Clin. Cancer Res. 16, 5956-5962 (2010).
36. Teicher, B.A. Antiangiogenic agents and targets: a perspective. Biochem. Pharmacol. 81, 6-12 (2011).
37. Ebos, J.M. & Kerbel, R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 8, 210-221 (2011).
38. Folkman, J., Watson, K., Ingber, D. & Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nature 339, 58-61 (1989).
39. Zucker, S., Cao, J. & Chen, W.T. Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment. Oncogene 19, 6642-6650 (2000).
40. Coussens, L.M., Fingleton, B. & Matrisian, L.M. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 295, 2387-2392 (2002).
41. Overall, C.M. & Kleifeld, O. Tumour microenvironment-opinion: validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy. Nat. Rev. Cancer 6, 227-239 (2006).
42. Roy, R., Yang, J. & Moses, M.A. Matrix metalloproteinases as novel biomarkers and potential therapeutic targets in human cancer. J. Clin. Oncol. 27, 5287-5297 (2009).
43. Folkman, J. Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp. Cell Res. 312, 594-607 (2006).
44. Boehm, T., Folkman, J., Browder, T. & O'Reilly, M.S. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 390, 404-407 (1997).
45. Karamouzis, M.V. & Moschos, S.J. The use of endostatin in the treatment of solid tumors. Expert Opin. Biol. Ther. 9, 641-648 (2009).
46. Kulke, M.H. et al. Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors. J. Clin. Oncol. 24, 3555-3561 (2006).
47. Bhargava, P. et al. A Phase I and pharmacokinetic study of TNP-470 administered weekly to patients with advanced cancer. Clin. Cancer Res. 5, 1989-1995 (1999).
48. Kim, K.J. et al. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362, 841-844 (1993).
49. Mesiano, S., Ferrara, N. & Jaffe, R.B. Role of vascular endothelial growth factor in ovarian cancer: Inhibition of ascites formation by immunoneutralization. Am. J. Pathol. 15, 1249-1256 (1998).
50. Allegra, C.J. et al. Phase III trial assessing bevacizumab in stages II and III carcinoma of the colon: results of NSABP protocol C-08. J. Clin. Oncol. 29, 11-16 (2011).
51. Burger, R.A. et al. Incorporation of bevacizumab in the primary treatment of ovarian cancer. N. Engl. J. Med. 365, 2473-2483 (2011).
52. Perren, T.J. et al. A phase 3 trial of bevacizumab in ovarian cancer. N. Engl. J. Med. 365, 2484-2496 (2011).
53. Pietras, K. & Hanahan, D. A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer. J. Clin. Oncol. 23, 939-952 (2005).
54. Raymond, E. et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. N. Engl. J. Med. 364, 501-513 (2011).
55. Ebos, J.M. et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 15, 232-239 (2009).
56. Paez-Ribes, M. et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 15, 220-231 (2009).
57. Sennino, B. et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2, 270-287 (2012).
58. Crawford, Y. & Ferrara, N. Tumor-and stromal pathways mediating refractoriness/resistance to anti-angiogenic therapies. Trends Pharmacol. Sci. 30, 624-630 (2009).
59. Bergers, G., Song, S., Meyer-Morse, N., Bergsland, E. & Hanahan, D. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 111, 1287-1295 (2003).
60. Xian, X. et al. Pericytes limit tumor cell metastasis. J. Clin. Invest. 116, 642-651 (2006).
61. Cooke, V.G. et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by Met signaling pathway. Cancer Cell 21, 66-81 (2012).
62. Miles, D. et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials. J. Clin. Oncol. 29, 83-88 (2011).
63. Rubenstein, J.L. et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2, 306-314 (2000).
64. Hanahan, D. & Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 144, 646-674 (2011).
65. Mellman, I., Coukos, G. & Dranoff, G. Cancer immunotherapy comes of age. Nature 480, 480-489 (2011).
66. de la Cruz-Merino, L., Grande-Pulido, E., Albero-Tamarit, A. & Codes-Manuel de Villena, M.E. Cancer and immune response: old and new evidence for future challenges. Oncologist 13, 1246-1254 (2008).
67. Tivol, E.A. et al. Loss of CTLA-4 leads to massive lymphoproliferation and fatal multiorgan tissue destruction, revealing a critical negative regulatory role of CTLA-4. Immunity 3, 541-547 (1995).
68. Waterhouse, P. et al. Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4. Science 270, 985-988 (1995).
69. Melero, I., Hervas-Stubbs, S., Glennie, M., Pardoll, D.M. & Chen, L. Immunostimulatory monoclonal antibodies for cancer therapy. Nat. Rev. Cancer 7, 95-106 (2007).
70. Kwon, E.D. et al. Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer. Proc. Natl. Acad. Sci. USA 94, 8099-8103 (1997).
71. Leach, D.R., Krummel, M.F. & Allison, J.P. Enhancement of antitumor immunity by CTLA-4 blockade. Science 271, 1734-1736 (1996).
72. van Elsas, A., Hurwitz, A.A. & Allison, J.P. Combination immunotherapy of B16 melanoma using anti-cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and granulocyte/macrophage colony-stimulating factor (GM-CSF)-producing vaccines induces rejection of subcutaneous and metastatic tumors accompanied by autoimmune depigmentation. J. Exp. Med. 190, 355-366 (1999).
73. Mokyr, M.B., Kalinichenko, T., Gorelik, L. & Bluestone, J.A. Realization of the therapeutic potential of CTLA-4 blockade in low-dose chemotherapy-treated tumor-bearing mice. Cancer Res. 58, 5301-5304 (1998).
74. Phan, G.Q. et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc. Natl. Acad. Sci. USA 100, 8372-8377 (2003).
75. Hodi, F.S. et al. Improved survival with ipilimumab in patients with metastatic melanoma. N. Engl. J. Med. 363, 711-723 (2010).
76. Wolchok, J.D. et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin. Cancer Res. 15, 7412-7420 (2009).
77. Sharma, P., Wagner, K., Wolchok, J.D. & Allison, J.P. Novel cancer immunotherapy agents with survival benefit: recent successes and next steps. Nat. Rev. Cancer 11, 805-812 (2011).
78. Callahan, M.K., Wolchok, J.D. & Allison, J.P. Anti-CTLA-4 antibody therapy: immune monitoring during clinical development of a novel immunotherapy. Semin. Oncol. 37, 473-484 (2010).
79. Hoos, A. et al. Development of ipilimumab: contribution to a new paradigm for cancer immunotherapy. Semin. Oncol. 37, 533-546 (2010).
80. Vanneman, M. & Dranoff, G. Combining immunotherapy and targeted therapies in cancer treatment. Nat. Rev. Cancer 12, 237-251 (2012).
81. Topalian, S.L. et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New Engl. J. Med. published online, doi:10.1056/NEJMoa1200690 (2 June 2012).
82. Brahmer, J.R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New Engl. J. Med. published online, doi: 10.1056/NEJMoa1200694 (2 June 2012).
83. Tlsty, T.D. & Coussens, L.M. Tumor stroma and regulation of cancer development. Annu. Rev. Pathol. 1, 119-150 (2006).
84. Crawford, Y. et al. PDGF-C mediates the angiogenic and tumorigenic properties of fibroblasts associated with tumors refractory to anti-VEGF treatment. Cancer Cell 15, 21-34 (2009).
85. Gilbert, L.A. & Hemann, M.T. DNA damage-mediated induction of a chemoresistant niche. Cell 143, 355-366 (2010).
86. Andreu, P. et al. FcRgamma activation regulates inflammation-associated squamous carcinogenesis. Cancer Cell 17, 121-134 (2010).
87. Coussens, L.M. et al. Inflammatory mast cells up-regulate angiogenesis during squamous epithelial carcinogenesis. Genes Dev. 13, 1382-1397 (1999).
88. Olumi, A.F. et al. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59, 5002-5011 (1999).
89. Shojaei, F. et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells. Nat. Biotechnol. 25, 911-920 (2007).
90. Erez, N., Truitt, M., Olson, P., Arron, S.T. & Hanahan, D. Cancer-associated fibroblasts are activated in incipient neoplasia to orchestrate tumor-promoting unflammation in an NF-κB-dependent manner. Cancer Cell 17, 135-147 (2010).
91. Gilbert, L.A. & Hemann, M.T. Chemotherapeutic resistance: surviving stressful situations. Cancer Res. 71, 5062-5066 (2011).
92. Teicher, B.A. In vivo/ex vivo and in situ assays used in cancer research: a brief review. Toxicol. Pathol. 37, 114-122 (2009).
93. Jia, J. et al. Mechanisms of drug combinations: interaction and network perspectives. Nat. Rev. Drug Discov. 8, 111-128 (2009).
94. Rottenberg, S. & Jonkers, J. Modeling therapy resistance in genetically engineered mouse cancer models. Drug Resist. Updat. 11, 51-60 (2008).
95. Zuber, J. et al. Mouse models of human AML accurately predict chemotherapy response. Genes Dev. 23, 877-889 (2009).
96. Pajic, M. et al. Moderate increase in Mdr1a/1b expression causes in vivo resistance to doxorubicin in a mouse model for hereditary breast cancer. Cancer Res. 69, 6396-6404 (2009).
97. Politi, K., Fan, P.D., Shen, R., Zakowski, M. & Varmus, H. Erlotinib resistance in mouse models of epidermal growth factor receptor-induced lung adenocarcinoma. Dis. Model Mech. 3, 111-119 (2010).
98. Sequist, L.V. et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci. Transl. Med. 3, 75ra26 (2011).
99. Sharma, S.V., Haber, D.A. & Settleman, J. Cell line-based platforms to evaluate the therapeutic efficacy of candidate anticancer agents. Nat. Rev. Cancer 10, 241-253 (2010).
100. Zhou, Y. et al. Chimeric mouse tumor models reveal differences in pathway activation between ERBB family-and KRAS-dependent lung adenocarcinomas. Nat. Biotechnol. 28, 71-78 (2010).
101. Shojaei, F. et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 450, 825-831 (2007).
102. Allen, E., Walters, I. & Hanahan, D. Brivanib, an FGF/VEGF inhibitor, is differentially active 1st vs. 2nd line against mouse PNET tumors developing evasive/adaptive resistance to VEGF inhibition. Clin. Cancer Res. 17, 5299-5310 (2011).
103. Casanovas, O., Hicklin, D.J., Bergers, G. & Hanahan, D. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8, 299-309 (2005).
104. Compagni, A., Wilgenbus, P., Impagnatiello, M.A., Cotten, M. & Christofori, G. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 60, 7163-7169 (2000).
105. Begley, C.G. & Ellis, L.M. Drug development: raise standards for preclinical cancer research. Nature 483, 531-533 (2012).
106. Maxmen, A. Translational research: the American way. Nature 478, S16-S18 (2011).
107. Schilsky, R.L. Accrual to cancer clinical trials in the era of molecular medicine. Sci. Transl. Med. 3, 75cm9 (2011).
108. Yap, T.A., Sandhu, S.K., Workman, P. & de Bono, J.S. Envisioning the future of early anticancer drug development. Nat. Rev. Cancer 10, 514-523 (2010).
109. Taguchi, A. et al. Lung cancer signatures in plasma based on proteome profiling of mouse tumor models. Cancer Cell 20, 289-299 (2011).
110. Chen, Z. et al. A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. Nature 483, 613-617 (2012).
111. Hanash, S.M., Baik, C.S. & Kallioniemi, O. Emerging molecular biomarkers-blood-based strategies to detect and monitor cancer. Nat. Rev. Clin. Oncol. 8, 142-150 (2011).
112. Mina, L.A. & Sledge, G.W. Jr. Rethinking the metastatic cascade as a therapeutic target. Nat. Rev. Clin. Oncol. 8, 325-332 (2011).
113. Premsrirut, P.K. et al. A rapid and scalable system for studying gene function in mice using conditional RNA interference. Cell 145, 145-158 (2011).
114. Schreiber, S.L. et al. Towards patient-based cancer therapeutics. Nat. Biotechnol. 28, 904-906 (2010).
115. Doyle, J.P. et al. Application of a translational profiling approach for the comparative analysis of CNS cell types. Cell 135, 749-762 (2008).
116. Heiman, M. et al. A translational profiling approach for the molecular characterization of CNS cell types. Cell 135, 738-748 (2008).
117. Sanz, E. et al. Cell-type-specific isolation of ribosome-associated mRNA from complex tissues. Proc. Natl. Acad. Sci. USA 106, 13939-13944 (2009).
118. Lesterhuis, W.J., Haanen, J.B. & Punt, C.J. Cancer immunotherapy-revisited. Nat. Rev. Drug Discov. 10, 591-600 (2011).
119. Scher, H.I., Nasso, S.F., Rubin, E.H. & Simon, R. Adaptive clinical trial designs for simultaneous testing of matched diagnostics and therapeutics. Clin. Cancer Res. 17, 6634-6640 (2011).
120. Sharma, M.R., Stadler, W.M. & Ratain, M.J. Randomized phase II trials: a long-term investment with promising returns. J. Natl. Cancer Inst. 103, 1093-1100 (2011).
121. Gerber, H.P. & Ferrara, N. Pharmacology and pharmacodynamics of bevacizumab as monotherapy or in combination with cytotoxic therapy in preclinical studies. Cancer Res. 65, 671-680 (2005).
122. Bruce, D. & Tan, P.H. Blocking the interaction of vascular endothelial growth factor receptors with their ligands and their effector signaling as a novel therapeutic target for cancer: time for a new look? Expert Opin. Investig. Drugs 20, 1413-1434 (2011).
123. Cao, Y. Antiangiogenic cancer therapy: why do mouse and human patients respond in a different way to the same drug? Int. J. Dev. Biol. 55, 557-562 (2011).
124. Gandhi, L. et al. Sunitinib prolongs survival in genetically engineered mouse models of multistep lung carcinogenesis. Cancer Prev. Res. (Phila.) 2, 330-337 (2009).
125. Scagliotti, G. et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J. Clin. Oncol. 28, 1835-1842 (2010).
126. Kindler, H.L. et al. Gemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303). J. Clin. Oncol. 28, 3617-3622 (2010).
127. Kindler, H.L. et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer. J. Clin. Oncol. 23, 8033-8040 (2005).
128. Olson, P., Chu, G.C., Perry, S.R., Nolan-Stevaux, O. & Hanahan, D. Imaging guided trials of the angiogenesis inhibitor sunitinib in mouse models predict efficacy in pancreatic neuroendocrine but not ductal carcinoma. Proc. Natl. Acad. Sci. USA 108, E1275-E1284 (2011).
129. Kindler, H.L. et al. Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol. 12, 256-262 (2011).